Benign%20prostatic%20hyperplasia News

News

LUTS reduction lowers risk of death in older men

Stephen Padilla, 20230925120000

A decrease in lower urinary tract symptoms (LUTS) results in a reduced risk of death among men with benign prostatic hyperplasia (BPH), suggests a study.

Trichomoniasis infection ups prostate cancer, benign prostate hyperplasia risk

Tristan Manalac, 20220920090000

Men with Trichomoniasis vaginalis infections appear to be at an elevated risk of prostate cancer (PCa) and benign prostate hyperplasia (BPH), according to a recent study.

Healthy lifestyle helps prevent, delay benign prostatic hyperplasia

20220705180000

Keeping healthy lifestyle habits, such as avoiding smoking, engaging in exercise, and limiting alcohol intake, helps prevent or delay the development of benign prostatic hyperplasia (BPH), a new Japan study has found.

HoLEP, RASP deliver equally excellent postoperative outcomes in benign prostatic hyperplasia

20220612060000

The use of holmium laser enucleation of the prostate (HoLEP) and robotic-assisted simple prostatectomy (RASP) deliver comparable and good postoperative outcomes in patients with large benign prostatic hyperplasia (BPH), a new study has found.

Long-term efficacy of Aquablation for BPH not dictated by prostate volume

20220501080000

Aquablation therapy appears to be effective in benign prostatic hyperplasia (BPH) patients experiencing lower urinary tract symptoms, with the favourable effects sustained over a 3-year follow-up while having few irreversible complications and low retreatment rates across all prostate volumes, according to a study.

Less is more when treating benign prostatic hyperplasia with thermal water vapour

20220210060000

Thermal water vapour therapy that consists of a single injection per prostate lobe for benign prostatic hyperplasia (BPH) is both effective and safe, yielding similar improvements in lower urinary tract symptoms and quality of life when compared with a traditional approach that employed variable number of injections by prostate volume, as shown in a study.

Original New Drug Application Approvals by US FDA (01-15 December 2021)

20211219151024

New drug applications approved by US FDA as of 01-15 December 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Second-gen implantable nitinol device delivers sustained relief of LUTS

Jairia Dela Cruz, 20210528140000

In men with lower urinary tract symptoms (LUTS) due to benign prostatic obstruction, temporary implantation of the second-generation nitinol device (iTIND) produces marked and durable improvements in symptoms and quality of life, as shown in a study.

Adjunctive use of vibegron feasible in BPH with persistent storage symptoms

20210127060000

Use of vibegron in addition to α-1 blocker or phosphodiesterase 5 (PDE5) inhibitor is safe and effective in the treatment of patients with benign prostatic hyperplasia (BPH) and persistent storage symptoms, as shown in a study.

Mirabegron safe to use as add-on in tamsulosin-treated male patients with LUTS

20201116060000

Mirabegron appears to be a safe add-on therapy in men receiving tamsulosin for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia, according to data from the phase IV PLUS study.

Antioxidant and micronutrient supplementation on the sperm parameters of male patients with idiopathic infertility: An updated literature review

09 Jun 2020

Infertility is a problem faced by 5-10 percent of couples, with male factor accounting for up to 47 percent of cases. [Int J Androl 1987;7(Suppl):1]. There are many causes for male infertility but up to 15 percent of cases are idiopathic in nature. These cases may be related to unregulated excessive oxidative stress, which may impair spermatogenesis; hence, arousing research into the role of antioxidant supplementation in improving the sperm parameters.

Denosumab: A critical aspect of metastatic prostate cancer treatment

Prof. Bertrand Tombal, Assoc Prof. Edmund Chiong, 18 May 2022

Men with metastatic prostate cancer (mPC) have an elevated risk of skeletal complications either due to bone metastases (skeletal-related events [SREs]), or from osteoporosis induced by androgen deprivation therapy (ADT). Two key opinion leaders recently shared their perspectives on bone complications in mPC as well as the use of bone-targeted agents (BTAs) such as denosumab (Xgeva) to reduce the risk of bone complications.

Professor Bertrand Tombal

Professor of Urology

Cliniques universitaires Saint-Luc & Université catholique de Louvain

Brussels, Belgium

Associate Professor Edmund Chiong

Head, Department of Urology

National University Hospital, Singapore

Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer

Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021

Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.